We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 12-1 yesterday that study data presented by Novartis to support a new indication for its blockbuster heart failure drug Entresto (sacubitril/valsartan) provided enough evidence. Read More